new_0222_0473|FDMT|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0473|FDMT|1|4D Molecular Therapeutics Inc Total Current Assets (Quarterly) (USD)|4D Molecular Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|4D Molecular Therapeutics Inc Inventories (Quarterly) (USD)|4D Molecular Therapeutics Inc Net PP&E (Quarterly) (USD)|4D Molecular Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|4D Molecular Therapeutics Inc Total Liabilities (Quarterly) (USD)|4D Molecular Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|4D Molecular Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|4D Molecular Therapeutics Inc Total Deposits (Quarterly) (USD)|4D Molecular Therapeutics Inc Book Value (Quarterly) (USD)|4D Molecular Therapeutics Inc Retained Earnings (Quarterly) (USD)|4D Molecular Therapeutics Inc Treasury Stock (Quarterly) (USD)|4D Molecular Therapeutics Inc EV to Revenues|4D Molecular Therapeutics Inc EV to Earnings|4D Molecular Therapeutics Inc EV to Free Cash Flow|4D Molecular Therapeutics Inc EV to Assets (Quarterly)|4D Molecular Therapeutics Inc PS Ratio|4D Molecular Therapeutics Inc PE Ratio|4D Molecular Therapeutics Inc Price to Book Value|4D Molecular Therapeutics Inc PEG Ratio|4D Molecular Therapeutics Inc Debt to Equity Ratio|4D Molecular Therapeutics Inc Dividend Yield|4D Molecular Therapeutics Inc Shareholder Yield (TTM)|4D Molecular Therapeutics Inc Percent of Shares Outstanding Short|4D Molecular Therapeutics Inc Total Receivables (Quarterly) (USD)|4D Molecular Therapeutics Inc Total Payables (Quarterly) (USD)|4D Molecular Therapeutics Inc Total Capital Stock (Quarterly) (USD)|4D Molecular Therapeutics Inc Return on Invested Capital|4D Molecular Therapeutics Inc Quality Ratio Score|4D Molecular Therapeutics Inc Momentum Score|4D Molecular Therapeutics Inc Beta (1Y)|4D Molecular Therapeutics Inc Sustainable Growth Rate (TTM)|4D Molecular Therapeutics Inc Institutional Investor Ownership Percentage|4D Molecular Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|4D Molecular Therapeutics Inc Total Employees (Annual)|4D Molecular Therapeutics Inc EPS Diluted (Quarterly) (USD)|4D Molecular Therapeutics Inc SG&A Expense (Quarterly) (USD)|4D Molecular Therapeutics Inc Shares Outstanding|4D Molecular Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|4D Molecular Therapeutics Inc Ordinary Shares Number (Quarterly)|4D Molecular Therapeutics Inc Payout Ratio|4D Molecular Therapeutics Inc Quick Ratio (Quarterly)|4D Molecular Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|4D Molecular Therapeutics Inc Stock Buybacks (Quarterly) (USD)|4D Molecular Therapeutics Inc Effective Tax Rate (TTM)|4D Molecular Therapeutics Inc Return on Equity|4D Molecular Therapeutics Inc Net Income (TTM) (USD)|4D Molecular Therapeutics Inc Revenue (TTM) (USD)|4D Molecular Therapeutics Inc Dividend Per Share (Quarterly) (USD)|4D Molecular Therapeutics Inc Revenue (Quarterly) (USD)|4D Molecular Therapeutics Inc Gross Profit (Quarterly) (USD)|4D Molecular Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|4D Molecular Therapeutics Inc Net Income (Quarterly) (USD)|4D Molecular Therapeutics Inc Net Interest Income (Quarterly) (USD)|4D Molecular Therapeutics Inc Price (USD)|4D Molecular Therapeutics Inc Total Return Price (USD)|4D Molecular Therapeutics Inc Enterprise Value (USD)|4D Molecular Therapeutics Inc 30-Day Average Daily Volume|4D Molecular Therapeutics Inc 1 Year Price Returns (Daily)|4D Molecular Therapeutics Inc Short Interest|4D Molecular Therapeutics Inc PE Ratio (Forward)|4D Molecular Therapeutics Inc PE Ratio (Forward 1y)|4D Molecular Therapeutics Inc PS Ratio (Forward)|4D Molecular Therapeutics Inc PS Ratio (Forward 1y)|4D Molecular Therapeutics Inc Quarterly EPS Estimates (USD)|4D Molecular Therapeutics Inc Quarterly Revenue Estimates (USD)|4D Molecular Therapeutics Inc Quarterly EPS Surprise|4D Molecular Therapeutics Inc Quarterly Revenue Surprise|4D Molecular Therapeutics Inc Quarterly Actual EPS (USD)|4D Molecular Therapeutics Inc Quarterly Actual Revenue (USD)|4D Molecular Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|4D Molecular Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|4D Molecular Therapeutics Inc Price Target (USD)|4D Molecular Therapeutics Inc Consensus Recommendation|4D Molecular Therapeutics Inc Price Target Num Estimates|4D Molecular Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|4D Molecular Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|4D Molecular Therapeutics Inc Research and Development Expense (Quarterly) (USD)|4D Molecular Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|4D Molecular Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|4D Molecular Therapeutics Inc Land and Improvements (Quarterly) (USD)|4D Molecular Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|4D Molecular Therapeutics Inc Other Properties (Quarterly) (USD)|4D Molecular Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0473|FDMT|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0473|FDMT|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0473|FDMT|5|143.428571429|143.428571429||143.428571429||143.428571429|143.428571429|143.428571429||143.428571429|143.428571429||1.45150501672|91|1.44755244755|91|1.45150501672||1.45150501672||91.2857142857|1.45150501672||15.2592592593|143.428571429|143.428571429|143.428571429|91|||31|91|30.4615384615|91.375|121.666666667|91.375|91.375|27.9166666667||143.428571429|91.4|91.2857142857|91.375|||91|91.4|91.4||91.375||91.375|91.375|91.375|1.45150501672|1.45150501672|1.45150501672|1.43703703704|1.42553191489|15.2592592593|||1.44755244755|1.45019920319|91.1428571429|91.1428571429|91|92|91|91|35.7272727273|25.9166666667|33.9166666667|13.1290322581|33.9166666667|25.4375|28.2727272727|91.375|91.375|||||143.428571429||
new_0222_0473|FDMT|6|7|7||7||7|7|7||7|7||299|3|286|3|299||299||7|299||27|7|7|7|3|||1|3|13|8|3|8|8|12||7|5|7|8|||3|5|5||8||8|8|8|299|299|299|270|47|27|||286|251|7|7|3|1|3|3|11|12|12|31|12|16|11|8|8|||||7||
new_0222_0473|FDMT|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0473|FDMT|201812|94.068|91.761||2.472||124.556|8.054|116.502||-27.587|-30.026||||||||||||||1.124|0.954|0.001|||||||||||||21.5956||||||||||||||||||||||||||||||||||||||||||||2.741||
new_0222_0473|FDMT|201906|75.445|72.869||4.026||122.804|8.603|114.201||-42.304|-46.235||||||||||||||1.161|1.296|0.001|||||||||||||21.5956||||||||||||||||||||||||||||||||||||||||||||3.487||
new_0222_0473|FDMT|201909||||||||||||||||||||||||||||||||||14.8353||-1.124|3.052||||||-1.124|||||||0.54||-16.675|-16.675|0.341||||||||||||||||||||||||9.374|0.28|||||||
new_0222_0473|FDMT|201912|52.508|49.652||5.049||131.204|12.955|118.249||-72.97|-79.025||||||||||||||0.978|1.744|0.001|||||||14.8353||-1.0863|5.959|||21.5956||3.9081|-1.0863|||||||2.03||-16.115|-16.115|0.218||||||||||||||||||||||||12.359|0.318|||||4.706||
new_0222_0473|FDMT|202003||||||||||||||||||||||||||||||||||14.8353||-0.8871|3.654||||||-0.8871|||||||3.535||-13.16|-13.16|0.13||||||||||||||||||||||||13.158|0.344|||||||
new_0222_0473|FDMT|202006||||||||||||||||||||||||||||||||||14.8353||-1.0214|3.062||||||-1.0214||||-61.103|9.738||3.633||-15.153|-15.153|0.014||||||||||||||||||||||||15.72|0.359|||||||
new_0222_0473|FDMT|202009|92.536|88.755||4.981||28.036|14.278|13.758||70.156|-115.132||||||||||||||0.896|1.292|0.002|||||||21.5956|78|-0.3627|3.682|||21.5956||6.279|-0.3627||||-52.261|16.619||7.421||-7.833|-7.833|0.004||||||||||||||||||||||||11.555|0.369|||||5.719||
new_0222_0473|FDMT|202012|282.656|276.726||5.073||31.944|16.744|15.2||256.387|-135.679||60.92|-14.6269|-15.9749|2.876|59.3402||4.3137|||||0.5961|1.486|1.787|0.003|-67.073||||-154.3238|77.0587|26.682|83|-0.7701|6.84|26.682||26.682||16.6156|-0.7701|||-154.3238|-56.693|13.612||-0.977||-20.547|-20.547|0.004|41.45|41.45|829.2429|147802.1||159055|||60.4487|713.5283|-0.66||-180.303||-1.85|-0.977|15.2097|9|53.6667|1.6667|3|-2.6367|-3.07|12.605|0.371|||||5.851|42.36|41.98
new_0222_0473|FDMT|202103|264.501|259.865||5.011||27.683|13.916|13.767||242.431|-152.085||74.3676|-14.9842|-16.8405|3.325|80.6421||4.7766|||||2.8141|0.965|1.284|0.003|-31.6037||||-66.0558|85.1058|26.6902||-0.61|5.543|26.6944||26.6944||18.7432|-0.61|||-66.0558|-59.939|12.077||2||-16.406|-16.406|0.007|43.38|43.38|898.1381|200419.9667||751197|||63.2927|747.0988|-1.1||44.5455||-0.61|2|6.9667|8|56|1.6667|3|-3.2267|-3.93|12.769|0.381|||||6.19|38.7|26.56
new_0222_0473|FDMT|202106|248.752|243.743||5.58||14.288|9.87|4.418||240.646|-159.674||17.5388|-7.7101|-6.3111|1.584|26.5929||2.6909|||||3.5223|1.218|1.962|0.003|-25.8763||||-35.5494|94.0139|26.7391|104|-0.28|6.953|26.8919||26.8919||24.8187|-0.28|||-35.5494|-52.375|23.024||14.58||-7.589|-7.589|0.007|24.08|24.08|403.814|157956.6667||947224|||35.3934|417.7787|-0.68|0.5875|58.8235|2381.7021|-0.28|14.58|5.0667|5.0333|52.3333|1.6667|3|-2.8|-2.99|15.223|0.37|||||6.581|24.87|30.55
new_0222_0473|FDMT|202109|165.733|161.675||8.789||16.484|11.373|5.111||224.134|-181.913||33.6485|-8.5501|-8.237|2.373|42.5687||3.2688|||||5.9039|0.791|3.713|0.003|-32.3002||||-32.3002|96.1738|27.0224|121|-0.82|8.187|27.1656||27.1656||14.2852|-0.82|||-32.3002|-66.781|16.969||1.366||-22.239|-22.239|0.435|26.97|26.97|570.9812|206674.8333||1603835|||40.0446|472.6814|-0.805|0.35|-1.8634|290.2857|-0.82|1.366|18.296|3.1|50.3333|1.6667|3|-2.5433|-3.6767|15.84|0.382|||||6.899|24.03|23
new_0222_0473|FDMT|202112|||||||||||||32.0261||-7.8398||34.6295||3.146|||||4.3477||||||2|0.5347||93.7142||||||||||||||||||||||21.94|21.94|543.4503|359705.2667|-47.0688|1397291|||116.8717|116.4988|-0.86|1.35|||||18.8307||45.25|1.5|4|-2.7825|||||||||15.8|13.97
new_0222_0473|FDMT|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.94|1||||||||||||||||||||
new_0222_0473|FDMT|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.975|1.5||||||||||||||||||||
new_0222_0473|FDMT|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.025|1.5||||||||||||||||||||